Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IFN-beta

IFN-beta

Brief Information

Name:Interferon beta
Target Synonym:Interferon Beta 1,Interferon, Beta 1, Fibroblast,IFNB,IFB,IFF,Interferon-beta,IFN-beta,Fibroblast interferon,IFNB1,Interferon beta
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 3 Clinical

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*
ACRO Quality

Synonym Name

IFNB1,Interferon beta,IFN-beta,IFB,IFNB

Background

Human type I interferons (IFNs) are a large subgroup of interferon proteins that help regulate the activity of the immune system. Interferons bind to interferon receptors. All type I IFNs bind to a specific cell surface receptor complex known as the IFN-¦Á receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains. The IFN-¦Â proteins are produced in large quantities by fibroblasts. They have antiviral activity that is involved mainly in innate immune response. Two types of IFN-¦Â have been described, IFN-¦Â1 (IFNB1) and IFN-¦Â3 (IFNB3) (a gene designated IFN-¦Â2 is actually IL-6). IFN-¦Â1 is used as a treatment for multiple sclerosis as it reduces the relapse rate. Furthermore, IFN-¦Â1 can bind to a IFNAR1-IFNAR2 heterodimeric receptor, and can also function with IFNAR1 alone and independently of Jak-STAT pathways.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VSV-IFNbeta-NIS Phase 2 Clinical Vyriad Endometrial Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Angioimmunoblastic T-cell Lymphoma; Mycosis Fungoides; Carcinoma, Endometrioid; Carcinoma, Neuroendocrine; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Colorectal Neoplasms; Carcinoma, Acinar Cell; Sarcoma; Adenocarcinoma, Clear Cell; Multiple Myeloma; Myelodysplastic Syndromes; Thyroid Carcinoma, Anaplastic; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Lymphoma, B-Cell Details
MEM-288 MEM-288 Phase 1 Clinical Memgen Solid tumours; Head and Neck Neoplasms; Carcinoma, Merkel Cell; Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma Details
Dazukibart PF-06823859 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Dermatomyositis; Myositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Muscular Diseases Details
Peginterferon beta-1a (CinnaGen) Phase 3 Clinical Cinnagen Multiple Sclerosis, Relapsing-Remitting Details
VSV-hIFNbeta-NIS (University of Tennessee) Phase 1 Clinical The University Of Tennessee Multiple Myeloma; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Endometrial Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message